Health Trials

HER2 Positive Advanced Gastric Cancer

2

Review clinical trials related to HER2 Positive Advanced Gastric Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This study will assess the effectiveness of T-DXd, patient demographic and clinical characteristics, and treatment patterns in patients with advanced HER2-positive advanced gastric or GEJ adenocarcinoma.

Participants needed: 257
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyUpdated: May 8, 2026Locations: 76Duration: 2 Years
Eligibility criteria

Male or female adult patient (age ≥ 18 years) with HER2 + advanced gastric or GE... [+4]

Patients who at time of data collection for this study are participating in or h... [+1]

Read more
Status: Recruiting

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.

Participants needed: 47
Trial details
Phase: Phase 1, Phase 2Biological sex: AllType: InterventionalSponsor: Kangbuk Samsung HospitalUpdated: Nov 26, 2024Locations: 1
Eligibility criteria

HER2-positive advanced gastric cancer [+10]

Patients who have received chemotherapy, radiation therapy, immunotherapy or tar... [+6]

Read more